Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer
KRAS mutations are frequent in pancreatic ductal adenocarcinoma, leading to bad prognosis and resistance to targeted therapies. Here, the authors show that LIF expression is specifically induced by KRAS and constitutes a potential target to treat these KRAS-mutated cancers.
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2019-07-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-019-11044-9 |